

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 March 2002 (21.03.2002)

PCT

(10) International Publication Number
WO 02/22664 A2

- (51) International Patent Classification⁷: **C07K 14/01**
- (21) International Application Number: PCT/EP01/10679
- (22) International Filing Date:
14 September 2001 (14.09.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
00203186.2 15 September 2000 (15.09.2000) EP
- (71) Applicant (*for all designated States except US*): **AKZO NOBEL N.V.** [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **VLAK, Justinus, Maria** [NL/NL]; Nieuwe Veenendaalseweg 214, NL-3911 Mr Rhenen (NL). **VAN HULTEN, Maria, Cornelia, Wilhelmina** [NL/NL]; Salverdaplein 10, NL-6701 DB Wageningen (NL).
- (74) Agent: **KEUS, Jacobus, A.R.**; P.O. Box 20, NL-5340 BH Oss (NL).
- (81) Designated States (*national*): AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: ANTIGENIC PROTEINS OF SHRIMP WHITE SPOT SYNDROME VIRUS AND USES THEREOF

(57) Abstract: The present invention relates to antigenic proteins derived from White Spot Syndrome virus having an estimated size of 19 kDa (VP 19) or 13 kDa (VP13), to the use of these proteins in vaccines and to vaccines on the basis of these proteins. Furthermore, the invention relates to antibodies against these proteins and to the use of antibodies in vaccines, to nucleic acid sequences encoding these proteins and to their use in vaccines. Also, the invention relates to the use of said proteins in the manufacture of a vaccine for prophylaxis and/or treatment of White Spot Syndrome in crustaceans, to vector vaccines and to diagnostic kits comprising said nuclei acids or antibodies.

WO 02/22664 A2